Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1999-5-13
pubmed:abstractText
IFN-gamma can either adversely or beneficially affect certain experimental autoimmune diseases. To study the role of IFN-gamma in the autoantibody-mediated experimental autoimmune myasthenia gravis (EAMG), an animal model of myasthenia gravis in humans, IFN-gammaR-deficient (IFN-gammaR-/-) mutant C57BL/6 mice and congenic wild-type mice were immunized with Torpedo acetylcholine receptor (AChR) plus CFA. IFN-gammaR-/- mice exhibited significantly lower incidence and severity of muscle weakness, lower anti-AChR IgG Ab levels, and lower Ab affinity to AChR compared with wild-type mice. Passive transfer of serum from IFN-gammaR-/- mice induced less muscular weakness compared with serum from wild-type mice. In contrast, numbers of lymph node cells secreting IFN-gamma and of those expressing IFN-gamma mRNA were strongly augmented in the IFN-gammaR-/- mice, reflecting a failure of negative feedback circuits. Cytokine studies by in situ hybridization revealed lower levels of lymphoid cells expressing AChR-reactive IL-1beta and TNF-alpha mRNA in AChR + CFA-immunized IFN-gammaR-/- mice compared with wild-type mice. No differences were found for AChR-reactive cells expressing IL-4, IL-10, or TGF-beta mRNA. These results indicate that IFN-gamma promotes systemic humoral responses in EAMG by up-regulating the production and the affinity of anti-AChR autoantibodies, thereby contributing to susceptibility to EAMG in C57BL/6-type mice.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
162
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3775-81
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:10201893-Animals, pubmed-meshheading:10201893-Antibody Affinity, pubmed-meshheading:10201893-Cells, Cultured, pubmed-meshheading:10201893-Cytokines, pubmed-meshheading:10201893-Female, pubmed-meshheading:10201893-Genetic Predisposition to Disease, pubmed-meshheading:10201893-Immune Sera, pubmed-meshheading:10201893-Immunization, Passive, pubmed-meshheading:10201893-Immunoglobulin G, pubmed-meshheading:10201893-Immunoglobulin Isotypes, pubmed-meshheading:10201893-Interferon-gamma, pubmed-meshheading:10201893-Lymphocyte Activation, pubmed-meshheading:10201893-Mice, pubmed-meshheading:10201893-Mice, Inbred C57BL, pubmed-meshheading:10201893-Mice, Knockout, pubmed-meshheading:10201893-Mice, Transgenic, pubmed-meshheading:10201893-Muscle Weakness, pubmed-meshheading:10201893-Myasthenia Gravis, pubmed-meshheading:10201893-RNA, Messenger, pubmed-meshheading:10201893-Receptors, Cholinergic, pubmed-meshheading:10201893-Receptors, Interferon
pubmed:year
1999
pubmed:articleTitle
Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
pubmed:affiliation
Division of Neurology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden. gxzhang@mail.med.upenn.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't